The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate
Kenneth A. Iczkowski(University of California, Davis), David G. Bostwick(University of Córdoba), Roger S. Rittmaster(Research Triangle Park Foundation), Gerald L. Andriole(Institut thématique Génétique, génomique et bioinformatique), Junqi Qian(Zhengzhou University), Matthew C. Somerville(PAREXEL International (United States)), Jingxin Qiu(University of Florida)
Cited by 80
Related Papers
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
|The Lancet|2018|1.8k
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
|Nature Genetics|2007|1.1k
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
|Controlled Clinical Trials|2000|1k
Colorectal-Cancer Incidence and Mortality with Screening Flexible Sigmoidoscopy
|New England Journal of Medicine|2012|1k